Prenosis

Prenosis is a pioneering diagnostics company at the intersection of artificial intelligence and precision medicine, focused on acute care conditions like sepsis. Its core asset is the FDA De Novo authorized Sepsis ImmunoScore®, an AI diagnostic that integrates into electronic health records and is also distributed via a partnership with Roche Diagnostics. The company is built on its proprietary Immunix™ platform, which leverages a vast biobank of clinical and biomarker data to develop and validate new tools. With a seasoned leadership team and a commercially authorized product, Prenosis is positioned to address a critical, high-cost area of hospital medicine.

Immunix™ precision medicine platform: an AI/ML-driven system built on a large biobank of longitudinal specimens linked to clinical data. It enables the development and real-time clinical implementation of diagnostic and prognostic tools for acute care conditions.

Prenosis competes in the emerging space of AI-driven clinical decision support for hospitals. Direct competitors include other startups developing sepsis prediction algorithms (e.g., Bayesian Health, Dascena). Indirect competitors include large diagnostic companies (e.g., bioMérieux, Becton Dickinson) integrating AI into their platforms, EHR vendors (e.g., Epic, Cerner) developing native predictive analytics, and large tech companies (e.g., Google Health) exploring healthcare AI. Prenosis's first-mover FDA authorization and Roche partnership are key differentiators.